EUnetHTA Joint Action 3 WP4: Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity

Source:
EUnetHTA
Publisher:
EUnetHTA
Publication date:
13 February 2020

Abstract

This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. This Joint Assessment aims to compare the clinical effectiveness and safety of siponimod in the target patient populations with relevant comparators according to the national requirements of EUnetHTA partners.